The 4 clinical trials currently active include the following studies (trial sites include MD Anderson Cancer Center and Oncology San Antonio):
- Treatment of patients with Progressive and/or Refractory Solid Malignancies
- Treatment of patients with Progressive and/or Refractory Hematologic Malignancies
- Consolidation therapy in patients with Metastatic Solid Malignancies
- Consolidation therapy in patients with Hematologic Malignancies
These protocols evaluate the effectiveness of Tumor Associated Peptide Antigens (TAPA) pulsed dendritic cell injections as a potential therapy for 4 different clinical scenarios for both solid and hematologic malignancies (most solid and hematologic indications are included such as prostate, breast, colon, pancreas, AML, etc). The investigators hypothesize that treatment of patients whose tumor cells and/or blood express at least one (1) TAPA of a defined panel of TAPAs will result in TAPA-specific T-cell responses without significant toxicities. The investigators also hypothesize CD4+ and CD8+ T-cell responses generated against specific TAPAs may translate into clinical antitumor activity.
To obtain more information about Kiromic’s clinical trials, please go to clinicaltrials.gov, and under Terms, search for BSK01. After reviewing the inclusion and exclusion criteria, if you are interested in possible enrollment, please contact the clinical study coordinator email@example.com.